Aisling Capital as of June 30, 2016
Portfolio Holdings for Aisling Capital
Aisling Capital holds 22 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Loxo Oncology | 22.1 | $93M | 4.0M | 23.18 | |
| Zeltiq Aesthetics | 13.6 | $58M | 2.1M | 27.33 | |
| Aimmune Therapeutics | 7.6 | $32M | 3.0M | 10.82 | |
| Viewray (VRAYQ) | 7.2 | $31M | 7.5M | 4.09 | |
| Versartis | 6.0 | $25M | 2.3M | 11.06 | |
| T2 Biosystems | 5.3 | $22M | 2.8M | 7.89 | |
| Adma Biologics (ADMA) | 5.1 | $22M | 3.6M | 5.95 | |
| Cempra | 4.7 | $20M | 1.2M | 16.49 | |
| Agile Therapeutics | 4.6 | $20M | 2.6M | 7.61 | |
| Cynapsus Therapeutics | 4.0 | $17M | 1.0M | 16.75 | |
| Syros Pharmaceuticals | 3.9 | $17M | 909k | 18.15 | |
| Esperion Therapeutics (ESPR) | 3.8 | $16M | 1.6M | 9.88 | |
| Catalent | 2.6 | $11M | 473k | 22.99 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 2.5 | $11M | 1.0M | 10.31 | |
| Transenterix | 2.4 | $10M | 8.3M | 1.22 | |
| Paratek Pharmaceuticals | 1.6 | $6.7M | 483k | 13.91 | |
| Intersect Ent | 1.4 | $5.8M | 450k | 12.93 | |
| Dermira | 0.7 | $3.0M | 103k | 29.25 | |
| Chimerix (CMRX) | 0.4 | $1.9M | 473k | 3.93 | |
| Lombard Med (EVARF) | 0.2 | $966k | 886k | 1.09 | |
| Pernix Therapeutics Holdings | 0.2 | $905k | 2.0M | 0.45 | |
| Pernix Therapeutics Hldgs In dbcv 4.250% 4/0 | 0.1 | $575k | 2.5M | 0.23 |
